# YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Source: https://onco.cc/trials/nct07461454/  
OnCo record `nct07461454` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing YL202 in HR-positive / HER2-negative breast cancer, now recruiting.

## Summary

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT07461454, led by MediLink Therapeutics (Suzhou), and recruiting on the registry. Official title: A Randomised, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy. Planned enrolment is 376 participants (estimated). The study started in 2026-03-17 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07461454
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy
- Sponsor: MediLink Therapeutics (Suzhou)
- Enrolled: 376

## Sources

- ClinicalTrials.gov NCT07461454: https://clinicaltrials.gov/study/NCT07461454

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [YL202](https://onco.cc/drugs/yl202/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07461454.json